Semaglutide journey TikToks: what the science actually backs

What did @antoniaa.k actually say?

The creator unboxed what appears to be compounded semaglutide, noted it arrived two days after ordering, and disclosed she weighs 176 pounds. Her main clinical claim: the starting dose of 0.25mg is "really a waste of time" and that "you don't really see results until like 0.5 or 1 milligram." She also mentioned she's been on semaglutide before, which she used to justify skipping ahead in the titration schedule.

That's the claim worth examining. Everything else, the unboxing theatrics, the syringes, the vials, is context. But dose-skipping advice, even framed casually, lands differently when 24,000 people are watching and some of them are about to start the same medication.

Does the science back this up?

Partially, but the framing is misleading in ways that matter. The 0.25mg starting dose was not designed to produce weight loss. It's a tolerability dose. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) used a structured four-week titration starting at 0.25mg before escalating, and participants who completed full titration achieved an average 14.9% body weight reduction. The low starting dose is the reason most people tolerate the drug at all.

That said, the creator is not wrong that meaningful weight loss is most consistently observed at 0.5mg and above. A dose-response analysis from the STEP program confirmed that higher doses correlate with greater weight reduction. But "waste of time" misrepresents why the 0.25mg period exists. It exists so your GI tract doesn't revolt. Studies report nausea and vomiting in roughly 44% and 25% of patients respectively at therapeutic doses (Davies et al., 2021, The Lancet). The ramp-up period is the buffer between tolerable and miserable.

What did they get wrong (or right)?

She got the general dose-response relationship right. More semaglutide typically means more weight loss, up to the approved ceiling. Credit where it's due.

What she got wrong is the implication that 0.25mg is clinically pointless. It is not a therapeutic dose, true, but it is a medically intentional step. If someone watches this video, decides 0.25mg is a waste of their time, and starts at 0.5mg without prior exposure to the drug, they are significantly more likely to experience nausea, vomiting, and early discontinuation. The clinical guidelines from the American Diabetes Association and the FDA-approved prescribing information for Wegovy both specify a minimum four-week period at 0.25mg before any escalation, with no exceptions for prior users unless under direct clinician supervision.

She also made a comment worth flagging: "I want to be skinny." That's honest, but semaglutide is approved for weight management in adults with a BMI of 30 or above, or 27 with a weight-related comorbidity. At 176 pounds, her eligibility depends entirely on her height, which she did not disclose. This isn't a criticism of her, it's a reminder that eligibility is not self-assessed.

What should you actually know?

The 0.25mg starting dose is not a placeholder. It's the reason most people don't quit semaglutide in week two. The titration schedule exists because GLP-1 receptor agonists slow gastric emptying, and your body needs time to adjust to that. Skipping ahead because you've "already been on it before" is not a clinically validated reason to bypass titration without a prescriber's explicit sign-off.

There is also a bigger issue in this video that nobody in the comments will talk about: this appears to be compounded semaglutide. The FDA has explicitly warned consumers that compounded semaglutide is not the same as FDA-approved Wegovy or Ozempic (FDA Safety Communication, 2023). Compounded versions are not reviewed for safety, efficacy, or potency by the FDA. That doesn't mean they don't work, but it does mean the dose printed on the vial may not reflect what's actually in the syringe. Anyone using compounded semaglutide should be doing so under close clinical supervision, not based on a TikTok titration timeline.

If you're considering semaglutide, talk to a licensed clinician. Do not use this video, or this fact-check, to make dosing decisions.